Eisai Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Eisai ha un patrimonio netto totale di ¥844.3B e un debito totale di ¥182.9B, che porta il suo rapporto debito/patrimonio netto a 21.7%. Le sue attività totali e le sue passività totali sono rispettivamente ¥1,321.4B e ¥477.1B. L'EBIT di Eisai è ¥40.5B rendendo il suo rapporto di copertura degli interessi -5.3. Ha liquidità e investimenti a breve termine pari a ¥268.6B.

Informazioni chiave

21.7%

Rapporto debito/patrimonio netto

JP¥182.90b

Debito

Indice di copertura degli interessi	-5.3x
Contanti	JP¥268.61b
Patrimonio netto	JP¥844.32b
Totale passività	JP¥477.10b
Totale attività	JP¥1.32t

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥681.9B ) di ESAL.F superano le sue passività a breve termine ( ¥326.8B ).

Passività a lungo termine: Le attività a breve termine di ESAL.F ( ¥681.9B ) superano le sue passività a lungo termine ( ¥150.3B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ESAL.F ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ESAL.F è aumentato da 18.2% a 21.7% negli ultimi 5 anni.

Copertura del debito: Il debito di ESAL.F non è ben coperto dal flusso di cassa operativo ( 15.1% ).

Copertura degli interessi: ESAL.F matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Eisai Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane